Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Table 2

The patients were divided into subgroups according to their clinical characteristics, and the impact of gene expression detection on prognosis was analysed.

Variable	Patient group; Experimental group vs. control group	Median DFS (months); Experimental group vs. control group	HR	95% CI	value
Tumour type
Squamous cell carcinoma	n = 19 vs. n = 17	16.00 vs. 14.00	0.7601	0.3518–1.642	0.4851
Adenocarcinoma	n = 20 vs. n = 9	21.00 vs. 10.00	0.5940	0.1951–1.808	0.3591
Stage
I	n = 16 vs. n = 12	36.00 vs. 12.00	0.4111	0.1468–1.151	0.0905
II	n = 12 vs. n = 8	16.00 vs. 16.50	1.404	0.4515–4.366	0.5577
III	n = 11 vs. n = 8	16.00 vs. 11.00	0.5853	0.1939–1.767	0.3419
Age, years
≤52	n = 19 vs. n = 16	16.00 vs. 10.5	0.5402	0.2313–1.262	0.1547
>52	n = 20 vs. n = 12	18.50 vs. 14.00	0.9117	0.3695–2.249	0.8409
Sex
Male	n = 28 vs. n = 23	16.00 vs. 11.00	0.5825	0.2882–1.177	0.1323
Female	n = 11 vs. n = 5	20.00 vs. 22.00	1.127	0.2981–4.258	0.8605
Treatment
Gemcitabine	n = 19 vs. n = 12	17.00 vs. 10.50	0.2147	0.07909–0.5827	0.0025
Paclitaxel	n = 20 vs. n = 16	16.00 vs. 22.50	1.041	0.4371–2.479	0.9279